MF
Matthew Frank
Research areas: Medicine · Oncology · CAR-T cell therapy research · Lymphoma Diagnosis and Treatment · T-cell and B-cell Immunology
0000-0002-2356-3354
Employment
Employment history is unavailable.
Education
Education history is unavailable.
Projects & Funding
Projects & funding information is unavailable.
Publications (154)
- How I treat HLH-like toxicities after immune effector cell therapy Save
- Post CAR-T Measurable Residual Disease Monitoring in Mantle Cell Lymphoma Enables Early Detection of Disease Relapse. Save
- Brexu-cel plus dasatinib: Safety and feasibility of dasatinib pulses after brexucabtagene autoleucel to modulate CAR T cell activity in relapsed/refractory B cell acute lymphoblastic leukemia Save
- Dynamics of BCMA expression in patients with relapsed/refractory multiple myeloma receiving BCMA-directed CAR-T therapy. Save
- Superior Chronic GVHD-Free Survival with Post-Transplant Cyclophosphamide Relative to Tacrolimus/Methotrexate in Myeloablative HLA-Matched Allogeneic Hematopoietic Cell Transplantation. Save
- Early Steroid and Anakinra Use to Manage Axicabtagene Ciloleucel Toxicity Reduces the Total Duration of CRS and ICANS. Save
- AI-Quantified Patient Frailty Predicts Clinical Response to CAR-T Save
- Characterization and Outcomes of Switching Tacrolimus to Sirolimus in Patients with Transplant-Associated Thrombotic Microangiopathy Save
- Impact of Social Determinants of Health on Access to CAR-T Therapy and Outcomes in Multiple Myeloma Patients Save
- Patient Characteristics, Toxicity, and Response after Real World Administration of Obecabtagene Autoleucel and Brexucabtagene Autoleucel for Relapsed Acute Lymphoblastic Leukemia: A Rocca Analysis Save
- Treatment kinetics and local response during and after bridging radiotherapy prior to CAR-T cell therapy for lymphomas. Save
- Clinical and Cytokine Features of Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome. Save
- Allogeneic HSC and regulatory T cell (Orca-T) engineered cell therapy following reduced intensity conditioning: Results of a single center Phase 1 study Save
- CD22-CAR T cell multiomic features linked to patient outcomes in CD19-CAR resistant large B cell lymphoma Save
- Double-dose axicabtagene ciloleucel (Axi-Cel-2) as second-line therapy for high-risk relapsed or refractory large B-cell lymphoma (r/rLBCL): Interim results from a Phase 1b study Save
- Firicabtagene autoleucel (firi-cel), a CD22-directed CAR T-cell therapy, for patients with relapsed/refractory large B-cell lymphoma: Results from the phase 2 study (FIRCE-1 Trial) Save
- Post-transplant cyclophosphamide vs tacrolimus/methotrexate: Improved GRFS, reduced NRM, and less severe GVHD in myeloablative HLA-matched allogeneic transplantation Save
- Pre-treatment CDI9 antigen density and multi-antigen profiling by calibrated quantitative flow cytometry correlates with CAR T efficacy in LBCL Save
- Real-world effectiveness and safety outcomes by age, comorbidity, frailty, and treatments prior to infusion in relapsed or refractory (R/R) follicular lymphoma patients treated with axicabtagene ciloleucel Save
- Sequential CD19 and CD22 CART for relapsed and refractory B cell ALL: Phase I results Save